Diagnostic value of 123Iodine-IBZM-scintigraphy for staging of malignant melanomas;Diagnostischer Wert der 123Iod-IBZM-Szintigraphie zum Staging von malignen Melanomen

NuklearMedizin

Volumn 36, Issue 1, 1997, Pages 1-6

  Henker, Corinne ^a,b   Bida, B ^a   Markwardt, J ^a   Schlag, P ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Section of Pathology   (Germany)

Author keywords

IBZM; melanoma; oncology

Indexed keywords

IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; METASTASIS; WHOLE BODY SCINTISCANNING; BRAIN TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SKIN TUMOR;

BENZAMIDES; BRAIN NEOPLASMS; DOPAMINE ANTAGONISTS; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRROLIDINES; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030614568     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629724     Document Type: Article

References (17)

1. Bolt AG, Forrest IS. Interaction between human melanoprotein and chlorpromazine derivatives. II. Spectro-photometric studies. Life Sci 1967; 6: 1258-92.
2. 123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labeling technique and first clinical results. Eur J Nucl Med 1993; 20: 238-43.
3. 2 fragments of monoclonal antibodies to a human high molecular weight melanoma associated antigen. J Nucl Med 1984; 28: 195-283.
4. 131I-labeled monoclonal antibodies to a high molecular weight melanoma associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res 1985; 45: 3378-87.
5. Coderre JA, Packer S, Fairchild RG et al. Iodothiouracil as a melanoma localizing agent. J Nucl Med 1986; 27: 1157-64.
6. de Paulis T, Kumar Y, Johansson L et al. Potential neuroleplic agents. 3. Chemistry and amidopaminergic properties of substituted 6-methoxysalicylamides. J Med Chem 1985; 28: 1263-9.
7. Fairchild RG, Greenberg D, Watts KP et al. Chlorpromazine distribution in hamsters and mice bearing transplantable melanoma. Cancer Res 1982; 42: 556-62.
8. Kung HF, Xu X-J, Guo Y-Z. Preparation and radiolabelling of IBZM: a potential D2 specific brain imaging agent for SPECT. J Labelled Compd Radiopharm 1986; 23: 1318-9.
9. 123I)-IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989; 30: 88-92.
10. 123I]IBZM uptake in metastatic melanoma. J Nucl Biol Med 1993; 37: 18-20.
11. Maffioli L, Mascheroni L, Mongioj V et al. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 1994; 35: 1741-7.
12. Michelot JM, Moreau MF, Labarre PG et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991; 32: 1573-80.
13. Michelot JM, Moreau MFC, Veyre AJ et al. Phase II Scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 1993; 34: 1260-6.
14. Rodot S, Darcourt J, Bussiere F et al. A radiolebelled iodobenzamide for malignant melanoma staging. Melanoma Res 1994; 4: 307-12.
15. 99mTelabeled monoclonal antibody fragments. Eur J Nucl Med 1990; 16: 317-23.
16. 67Ga citrate. Ear J Nucl Med 1986; 12: 96-104.
17. Verhoeff NPLG, Busemann Sokole E, Stabin M et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med 1993; 20: 747-52.